4665
Last Update Posted: 2005-06-24
Recruiting has ended
Females accepted | 18 Years + |
20 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
OBJECTIVES:
I. Evaluate the long-term safety and tolerance of a synthetic formulation of dehydroepiandrosterone, GL701, in patients with systemic lupus erythematosus who have completed a prior GL701 protocol.
PROTOCOL OUTLINE: Patients receive daily oral dehydroepiandrosterone for 12 months. The dose is adjusted based on disease activity and tolerance of treatment.
Patients are followed every 3 months.
Eligibility
Relevant conditions:
Systemic Lupus Erythematosus
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov